

Department of Health

COVID-19 Update



December 21, 2021

Charlotte Update

23,693 total cases

- July 2021-1,368 July 2020- 1,195
- August 2021- 4,660 August 2020- 732
- September 2021- 2,884 September 2020- 378
- October 2021- 764 October 2020- 662
- November 2021- 339 November 2020- 1,387
- December 2021-376 December 2020-2,411

New weekly case Positivity 3.9%, State Average 5.4%

- Overall positivity for outbreak 19.4%; State 20.3%
- Approx. 2,412 tests performed last 7 days.

132,039 Vaccinated Roughly 72% of 5+ eligible population.

93% over 65 vaccinated. 44,512 additional doses.

Monoclonal site data not available as we transition to local model.


Case Trends

Cases & Deaths in Charlotte County, Florida

Data through Sat Dec 18 2021

Total Cases (last 7 days)	144
Case Rate (last 7 days)	76.23
% Change (last 7 days)	22.03

Total Deaths (last 7 days)	<10
Death Rate (last 7 days)	suppressed
% Change (last 7 days)	



Testing

Testing in Charlotte County, Florida

Data through Thu Dec 16 2021

% Positivity (last 7 days)	6.37
% Change (last 7 days)	2.25

Data through Sun Dec 12 2021


Tests Performed (last 7 days)	2412
Test Rate (last 7 days)	1238.76
% Change (last 7 days)	-4.51

Tue, Jan 21st 2020 - Sat, Dec 18th 2021


Use slider to update time series chart



7-day Percent Positivity



Daily Tests Performed - 7-Day Moving Average



Hospitalizations

Hospitalizations in Charlotte County, Florida

Data through Fri Dec 17 2021



New Admissions (last 7 days)	13
Rate of New Admissions per 100 beds (last 7 days)	1.96
Rate of New Admissions per 100k people (last 7 days)	6.88
% Change (last 7 days)	18.18

% Beds Used (last 7 days)	2.5
% Change (last 7 days)	0.57

% ICU Beds Used (last 7 days)	7.97
% Change (last 7 days)	2.42


Tue, Jan 21st 2020 - Sat, Dec 18th 2021

Use slider to update time series chart




Influenza-Like Illness Updates

Figure 10: In week 48, the percent of specimens testing positive for **rhinovirus, adenovirus, and parainfluenza 1-3** increased while **RSV and influenza unspecified** remained consistent and **human metapneumovirus** decreased when compared with previous weeks. This information may change as additional data are received.



▲ Figure 10 shows the percent of laboratory results testing positive for eight common respiratory viruses, as reported by laboratories participating in the National Respiratory and Enteric Virus Surveillance System (NREVSS) and laboratories reporting validated respiratory virus data to the Florida Department of Health via electronic laboratory reporting (n=4), week 30, 2021 to week 48, 2021.

Figure 6: In week 48, the percent of emergency department and urgent care center visits for ILI statewide decreased slightly. Levels were similar to those observed at this time in previous seasons.



◀ Figure 6 shows the percent of visits for influenza-like illness (ILI) for facilities participating in ESSENCE-FL* (n=410) statewide for the current season (week 40, 2021 to week 48, 2021) and the previous three seasons (2020-21, 2019-20, and 2018-19).

Figure 7: ILI has previously been used to represent influenza activity, but now is important to view in the context of diagnoses for common viral respiratory pathogens. In week 48, the number of visits with a discharge diagnosis of influenza increased compared to visits with other viral respiratory related diagnoses (Coronavirus Disease 2019 (COVID-19), respiratory syncytial virus (RSV)).



Strategy/Updates

Vaccine Manufacturer	Pfizer-BioNTech	Moderna	Johnson & Johnson's Janssen
Who Can Get This Vaccine?	People 5 years and older	People 18 years and older	People 18 years and older
Number of Shots?	2 shots given 21 days apart	2 shots given 28 days apart	1 shot
When Are You Considered Fully Vaccinated?	2 weeks after second shot	2 weeks after second shot	2 weeks after shot
Additional Dose	Recommended for moderately to severely immunocompromised people. Given 4 weeks after second shot.	Recommended for moderately to severely immunocompromised people. Given 4 weeks after second shot.	Not recommended at this time.
Booster Dose	<p>You are eligible for a booster if you are:</p> <ul style="list-style-type: none"> 65 years or older Age 18+ who live in long term care settings Age 18+ who have underlying medical conditions Age 18+ who work or live in high risk settings <p>When to get a booster: At least 6 months after second shot.</p> <p>Heterologous Booster Dose is Allowed.</p>	<p>You are eligible for a booster* if you are:</p> <ul style="list-style-type: none"> 65 years or older Age 18+ who live in long term care settings Age 18+ who have underlying medical conditions Age 18+ who work or live in high risk settings <p>*Booster dose is a half-dose (.25mL)</p> <p>When to get a booster: At least 6 months after second shot.</p> <p>Heterologous Booster Dose is Allowed.</p>	<p>You are eligible for a booster if you are:</p> <ul style="list-style-type: none"> 18 years or older <p>When to get a booster: At least 2 months after shot.</p> <p>Heterologous Booster Dose is Allowed.</p>

- Continue current testing and vaccination strategies.
- Monoclonal site will remain open and bill insurances. (Demobilized by state on 12/11.
- Support onsite testing and vaccinations at targeted locations.
- Expansion of testing availability with partners.
- Continue rapid Infection control assessments.
- Booster shots support per CDC guidance.
- Pediatric Immunizations continue.
- Focus on recovery and holiday celebrations.
- Continued focus on ILI and respiratory illnesses.
- Continue to monitor emerging variants and respond appropriately.

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html>



EARLY TREATMENT SAVES LIVES

NEW PREVENTATIVE MONOCLONAL ANTIBODY THERAPY EVUSHELD

IT IS A LONG-ACTING MONOCLONAL ANTIBODY THERAPY FOR PRE-EXPOSURE PREVENTION.

REDUCES THE RISK OF DEVELOPING COVID-19 BY 77% IN CLINICAL TRIALS.

THIS PRODUCT IS AUTHORIZED SPECIFICALLY FOR:

- **INDIVIDUALS WHO ARE IMMUNOCOMPROMISED OR ARE TAKING IMMUNOSUPPRESSIVE MEDICATIONS - AND MAY NOT HAVE AN ADEQUATE IMMUNE RESPONSE TO THE VACCINE SUCH AS CANCER PATIENTS OR TRANSPLANT RECIPIENTS.**
- **INDIVIDUALS WITH A HISTORY OF SEVERE ADVERSE REACTIONS TO THE VACCINE OR ITS INGREDIENTS.**

ONLY AUTHORIZED FOR THOSE WHO ARE NOT CURRENTLY INFECTED OR HAVE NOT BEEN RECENTLY EXPOSED TO COVID.

CAN PROVIDE THE PROTECTION IMMUNOCOMPROMISED AND OTHER MEDICALLY VULNERABLE PEOPLE NEED FOR AT LEAST SIX MONTHS.

FLORIDA LEADS IN PREVENTING AND TREATING COVID-19.

Discussion

Thank you.